Aspirin use and risk of breast cancer: Systematic review and meta-analysis of observational studies

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 11, 2015, Pages 1645-1655

  Zhong, Shanliang ^a   Chen, Lin ^b   Zhang, Xiaohui ^a   Yu, Dandan ^a   Tang, Jinhai ^a   Zhao, Jianhua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HORMONE RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT;

BREAST CANCER; BREAST TUMOR; CANCER RISK; COHORT ANALYSIS; DRUG USE; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PUBLISHING; REVIEW; RISK FACTOR; STUDY DESIGN; SYSTEMATIC REVIEW; BREAST NEOPLASMS; FEMALE; RISK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BREAST NEOPLASMS; FEMALE; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; RISK;

EID: 84946556120     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0452     Document Type: Review

References (71)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Lazzeroni M, Petrera M, Marra D, Decensi A. Aspirin and breast cancer prevention. Curr Breast Cancer Rep 2013;5:202-7.
3. Thorat MA, Cuzick J. Role of aspirin in cancer prevention. Curr Oncol Rep 2013;15:533-40.
4. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012;9:259-67.
5. Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM, et al. Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and metaanalysis. Int J Cancer 2013;132:1146-55.
6. Zhong S, Zhang X, Chen L, Ma T, Tang J, Zhao J. Association between aspirin use and mortality in breast cancer patients:a meta-analysis of observational studies. Breast Cancer Res Treat 2015;150:199-207.
7. Luo T, Yan HM, He P, Luo Y, Yang YF, Zheng H. Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2012;131:581-7.
8. Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1586-91.
9. Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, Zauber AG, et al. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 1999;29:72-6.
10. Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, et al. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 2011;126:149-55.
11. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 2005;162:165-70.
12. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
13. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 2004;24:3177-84.
14. Wells G, Shea B, O'Connell D, Robertson J, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing thequality ofnonrandomised studies in meta-analyses. www.ohri.ca/programs/clinical-epidemiology/oxford-web.ppt. 2010.
15. Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J Educ Behav Stat 2005;30:261-93.
16. Raudenbush SW. Analyzing effect sizes: random-effects models. In: Cooper H, Hedges LV, Valentine JC, editors. The Handbook of Research Synthesis and Meta-analysis. New York: Russell Sage Foundation; 2009. p. 295-316.
17. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects metaanalyses. BMJ 2011;342:d549.
18. Brasky TM, Liu J, White E, Peters U, Potter JD, Walter RB, et al. Non-steroidal anti-inflammatory drugs and cancer risk in women: Results from the Women's Health Initiative. Int J Cancer 2014;135:1869-83.
19. Lee HH, Tsan YT, Ho WC, Lin MH, Lee CH, Tseng CD, et al. Angiotensinconverting enzyme inhibitors enhance the effect of cyclooxygenase inhibitors on breast cancer: a nationwide case-control study. J Hypertens 2012;30:2432-9.
20. Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L. Regular aspirin use and breast cancer risk in US Black women. Cancer Causes Control 2011;22:1553-61.
21. Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. Arch Intern Med 2009;169:115-21.
22. Gierach GL, Lacey JV Jr, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 2008;10:R38.
23. Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 2007;166:1150-8.
24. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-15.
25. Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 2005;97:805-12.
26. Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 2005;5:159.
27. Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology 2005;68:40-7.
28. Garcia Rodriguez LA, Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 2004;91:525-9.
29. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003;63:6096-101.
30. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal antiinflammatory drugs and breast cancer. Oncol Rep 1999;6:71-3.
31. Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol 2012;30:3468-77.
32. Kirsh VA, Kreiger N, Cotterchio M, Sloan M, Theis B. Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol 2007;166:709-16.
33. Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, et al. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev 2007;16:747-55.
34. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
35. Hedges LV, Pigott TD. The power of statistical tests in meta-analysis. Psychol Methods 2001;6:203-17.
36. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
37. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63.
38. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 2012;175:66-73.
39. Jackson D, White IR, Thompson SG. Extending Der Simonian and Laird's methodology to perform multivariate random effects meta-analyses. Stat Med 2010;29:1282-97.
40. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010;36:1-48.
41. Crippa A, Orsini N. Dosresmeta: Performing multivariate dose-response meta-analysis. Vienna, Austria: R Foundation for Statistical Computing; 2013.
42. Poynter JN, Inoue-Choi M, Ross JA, Jacobs DR Jr, Robien K. Reproductive, lifestyle, and anthropometric risk factors for cancer in elderly women. Cancer Epidemiol Biomarkers Prev 2013;22:681-7.
43. Davis S, Mirick DK. Medication use and the risk of breast cancer. Eur J Epidemiol 2007;22:319-25.
44. Harris R, Namboodiri K, Farrar W. Epidemiologic-study of nonsteroidal antiinflammatory drugs and breast-cancer. Oncol Rep 1995;2:591-2.
45. Friedman GD, Ury HK. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980;65:723-33.
46. Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control 2011;22:965-75.
47. Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM. Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res 2006;8:R71.
48. Jacobs EJ, Thun MJ, Connell CJ, Rodriguez C, Henley SJ, Feigelson HS, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U. S.cohort. Cancer Epidemiol Biomarkers Prev 2005;14:261-4.
49. Cotterchio M, Kreiger N, Sloan M, Steingart A. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:1213-7.
50. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996;88:988-93.
51. Lee HH, Tsan YT, Ho WC, Lin MH, Lee CH, Tseng CD, et al. Angiotensinconverting enzyme inhibitors enhance the effect of cyclooxygenase inhibitors on breast cancer: a nationwide casecontrol study. Value in Health 2012;15:A654.
52. Lee HH, Tsan YT, Ho WC, Lin MH, Lee CH, Tseng CD, et al. Angiotensinconverting enzyme inhibitors enhance the effect of cyclooxygenase inhibitors on breast cancer: aa nationwide case-control study. Epidemiology 2012;23:S590.
53. Hollestein LM, Van Herk-Sukel MPP, Ruiter R, De Vries E, Mathijssen RHJ, Wiemer EAC, et al. Incident cancer risk after the start of aspirin use: results from a Dutch population-based cohort study of lowdose aspirin users. Int J Cancer 2014;135:157-65.
54. Friis S, Thomassen L, Sorensen HT, Tjonneland A, Overvad K, Cronin-Fenton DP, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 2008;17:88-96.
55. Ready A, Velicer CM, McTiernan A, White E. NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 2008;109:533-43.
56. Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ. Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 2007;121:211-5.
57. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
58. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989;299:1247.
59. Cui Y, Deming-Halverson SL, Shrubsole MJ, Beeghly-Fadiel A, Cai H, Fair AM, et al. Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women. Breast Cancer Res Treat 2014;146:439-46.
60. Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, et al. Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 2010;21:1503-12.
61. Cronin-Fenton DP, Pedersen L, Lash TL, Friis S, Baron JA, Sorensen HT. Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Res 2010;12:R15.
62. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006;6:27.
63. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004;291:2433-40.
64. Moorman PG, Grubber JM, Millikan RC, Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003;14:915-22.
65. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996;7:203-5.
66. Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, et al. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998;7:869-73.
67. Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 2004;6:213-8.
68. Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE. Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2010;19:1033-41.
69. Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA. Tumor variants by hormone receptor expression in white patients with nodenegative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol 2001;19:18-27.
70. Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007;9:210.
71. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167:492-9.